Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders

This article was originally published here

GPA and MPA are rare and potentially life-threatening diseases, which affect small and medium-sized blood vessels. The FDA approval was based on data from the PePRS phase IIa,

The post Roche gets FDA nod for Rituxan to treat children with two blood vessel disorders appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply